Stifel Affirms Buy on DexCom, Keeps $85 Price Target After Q4 Results
Stifel has reiterated a Buy rating on DexCom and maintained an $85.00 price target after the company’s fourth-quarter report, a level Stifel says is closely aligned with InvestingPro’s Fair Value assessment. The brokerage pointed to management’s upbeat commentary on sell-through trends that extended into early 2026, steady financial metrics and ups…